

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/017,817	12/14/2001	James N. Chang	D-3011	5033
33197	7590 03/25/2004		EXAMINER	
STOUT, UX	A, BUYAN & MULLIN	FAY, ZOHREH A		
4 VENTURE, SUITE 300 IRVINE, CA 92618			ART UNIT	PAPER NUMBER
ikvine, ca	92010		1614	
			DATE MAILED: 03/25/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
,		10/017,817	CHANG ET AL.			
0	ffice Action Summary	Examiner	Art Unit			
		Zohreh Fay	1614			
The Period for Rep	MAILING DATE of this communication a ply	ppears on the cover sheet w	rith the correspondence address			
THE MAILI - Extensions of after SIX (6) - If the period - If NO period - Failure to repany reply rec	ENED STATUTORY PERIOD FOR REFING DATE OF THIS COMMUNICATION of time may be available under the provisions of 37 CFR MONTHS from the mailing date of this communication. for reply specified above is less than thirty (30) days, a refor reply is specified above, the maximum statutory period within the set or extended period for reply will, by staticeived by the Office later than three months after the main term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a reply within the statutory minimum of thi od will apply and will expire SIX (6) MO tute, cause the application to become A	reply be timely filed irreply be timely filed irreply. INTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).			
Status						
1)☐ Resp	oonsive to communication(s) filed on					
	☐ This action is FINAL . 2b) ☐ This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
close	ed in accordance with the practice unde	er Ex parte Quayle, 1935 C.I	D. 11, 453 O.G. 213.			
Disposition of	f Claims					
4)⊠ Clair	m(s) <u>1-34</u> is/are pending in the applicati	on.				
4a) C	of the above claim(s) is/are withd	Irawn from consideration.				
5)∭ Clair	m(s) is/are allowed.					
,	m(s) <u>1-34</u> is/are rejected.					
•	m(s) is/are objected to.					
8)∏ Clair	m(s) are subject to restriction and	d/or election requirement.				
Application P	apers					
	specification is objected to by the Exam					
	drawing(s) filed on is/are: a)□ a					
	icant may not request that any objection to t					
	acement drawing sheet(s) including the con					
11)∐ The o	oath or declaration is objected to by the	Examiner. Note the attache	ad Office Action of John F10-132.			
-	r 35 U.S.C. § 119					
	nowledgment is made of a claim for fore	ign priority under 35 U.S.C.	§ 119(a)-(d) or (f).			
a)∏ Al	,					
1.	,		A 15 (5 No.			
2						
3.	Copies of the certified copies of the p		in received in this National Stage			
* Coo #	application from the International Bur he attached detailed Office action for a		ot received			
See ti	ie attached detailed Office action for a	not of the continue copies he				
Attachment(s)						
1) Notice of R	References Cited (PTO-892)	Daner M	v Summary (PTO-413) o(s)/Mail Date			
	Oraftsperson's Patent Drawing Review (PTO-948) n Disclosure Statement(s) (PTO-1449 or PTO/SB	·	of Informal Patent Application (PTO-152)			
	s)/Mail Date	6) Other: _	<u></u>			

Application/Control Number: 10/017,817

Art Unit: 1614

Claims 1-34 are presented for examination.

The remarks filed on November 17, 2003 have been received and entered.

Claims 1-5, 7, 9-25 and 31-34 are again rejected under 35 U.S.C. 112 first paragraph for the reasons set forth on page 2 of the office action of August 19, 2003.

Claims 1-34 are rejected under 35 U.S.C. 103 as being unpatentable over Dikstein (U.S. Patent 5,106,615). Diskstein teaches the use of polyanionic polymers such as polyacrylates, cellulose derivatives in an ophthalmic formulation as an artificial tear. See page 3, paragraph 10, page 5, paragraph 21. The above reference also teaches the addition of secondary components such as preservatives and buffering agents. See page 8, lines 39 and 40. The mixture of anionic polymers is also taught by the above reference. See example 3. The above reference differs from the claimed invention in the specific proportions or amounts. It would have been obvious to a person skilled in the art to use the claimed polymers and the mixture thereof in an ophthalmic formulation, considering that the prior art teaches that polyanionic polymers and the mixtures thereof have been previously used in the ophthalmic formulation. The determination of optimum amounts or proportions are considered to be within the skill of artisan in the absence of evidence to the contrary.

One skilled in the art would have been motivated to employ the teachings of the above reference, since it relates to the use of polyanionic agents in ophthalmic formulation. The determination of optimum proportions or amounts are considered to be within the skill of artisan in the absence of evidence to the contrary. Applicant has

Application/Control Number: 10/017,817

Art Unit: 1614

presented no evidence to establish the unexpected or unobvious nature of the claimed invention, and as such, claims 1-34 are properly rejected under 35 U.S.C. 103.

Applicant's arguments and remarks regarding the 112 first paragraph rejections have been carefully considered, but are not deemed to be persuasive. Applicant's claims are drawn to the use of the mixture of any polyanionic agent. The specification indicates the use of a few of such compounds. However, such examples are not commensurate in scope with the broad phrases as claimed herein. Since each polymer structure and activity for such agents must be determined from case to case by painstaking experimental study, one of ordinary skill in the art would have been burdened with undue experimentation to determine all the polyanionic polymers and the mixture thereof which would be capable of being used together and be useful as artificial tear for treating dry eye syndrome.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh Fay whose telephone number is (703) 308-4604. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Z.F

Page 4